6 February 2026 | 6:11AM HKT Equity Research Victory Giant (300476.SZ): Mgmt. visit: AI PCB dollar content increase driving growth; Efficient capacity expansion to support clients; Buy We hosted Victory Giant's board secretary in Hong Kong recently. Management is positive on the PCB dollar content increase in AI servers and is working closely with the major customer on the next generation products, meanwhile expanding to ASIC AI server supply chain, driving the revenue growth in the coming years. Management ...

6 February 2026 | 6:39AM HKT Equity Research Shengyi Tech (600183.SS): PCB Factory Tour: AI CCL price increase; Solid demand along with M9 migrations We hosted Shengyi Tech's management and visited its Dongguan factory during our China PCB Tour on Jan 28. Key discussions were on CCL pricing trend, raw material cost increase and demand outlook. Overall, management expect full UT rate for the whole year, with solid orders at hand. With the faster-than-expected raw material price increase, the company raised p ...

Summary of the Conference Call on Shafeng Cement Industry Overview - The cement industry is experiencing a slow recovery in prices due to multiple factors, including seasonal influences and policy support, which may drive prices up in the future [1][2] - The company maintains a cautious strategy focused on stability despite optimistic expectations for demand recovery in infrastructure and real estate sectors [1][2] Company Performance - Shafeng Cement's sales remain stable with no significant decline in demand observed [4] - The company holds an optimistic outlook for 2026, particularly in regions like Xinjiang, Yunnan-Guizhou, and Ningxia, with Ningxia expected to see substantial growth in 2025 [5] - Five cement production lines in Anhui have been successfully replaced, while no replacements have occurred in the Southwest and Northwest regions due to low operating rates [6] Cost and Profitability - The company has a cost advantage in aggregate production, with plans for growth in East China and Southwest regions despite a recent decline in aggregate prices [8] - Overall profitability remains strong due to low costs and volume growth, even as margins stabilize [9] Investment Strategy - Shafeng Cement is focusing on investments in the semiconductor sector, aligning with national policies for domestic substitution, with significant projects like Changxing and Shenghe Jingwei entering the second return phase [10][12] - The company plans to invest approximately 3 to 5 billion annually in materials and semiconductor materials, maintaining a balance with dividend payouts [12] Future Plans - The company aims to continue its focus on semiconductor materials, specifically silicon-based and carbon-based materials, while also considering new energy materials [16] - A dividend plan is set to distribute 4 to 6 billion or 35% of net profit annually from 2024 to 2026, with specific amounts to be confirmed in April [18] Key Takeaways - Shafeng Cement is strategically positioned to leverage recovery in the cement market while actively investing in high-potential sectors like semiconductors - The company’s cautious yet optimistic approach reflects a commitment to maintaining profitability and supporting growth through targeted investments and cost management [1][2][10][12]

Summary of Jiangsu Zhongtian Technology Co. Ltd. Conference Call Company Overview - **Company Name**: Jiangsu Zhongtian Technology Co. Ltd. (600522.SS) - **Industry**: Utilities, specifically focusing on optical fiber, power transmission, and marine systems Key Points and Arguments Price Target and Valuation - The price target has been raised by 21.3% from Rmb24.27 to Rmb29.45, indicating a positive outlook for the company [1] - The company is currently trading at an appealing P/E of 17.1x for 2026 estimates, compared to a historical peak of 29.1x over the past five years [5][19] - The new price target implies a P/E of 22.9x for 2026 estimates, with a PEG ratio of approximately 0.5x [5] Optical Fiber Market Dynamics - Jiangsu Zhongtian Technology (ZTT) is positioned as a direct beneficiary of the optical fiber upcycle, with spot prices for optical fiber increasing significantly since Q4 2025, driven by demand from AI data centers and supply constraints [2] - The company expects elevated prices to persist through 2026, with normalization anticipated in 2027 [2] - ZTT is operating near full capacity of approximately 90 million core-km, with a 40% export mix [2] Offshore Wind Development - Anticipated acceleration in both domestic and overseas offshore wind projects, particularly in China and Europe [3] - In China, a breakthrough in offshore deep-sea development is expected during the 15th Five-Year Plan, with projected installations of 15-20GW annually from 2027 to 2030 [3] - ZTT has a substantial order backlog of Rmb3.2 billion for subsea cables, with full delivery expected by 2027 [3] Power Transmission Growth - China's confirmed grid capex plan and an export surge are expected to fuel growth in power transmission [4] - ZTT's power transmission revenue is forecasted to grow by 15% annually from 2026 to 2027 [4] - The company aims to increase its export mix of land cables to 25-30% in the coming years, up from the current 17-18% [4] Financial Projections - Revenue for the optical information and communication segment is projected to grow by 25% YoY in 2026, reaching Rmb10 billion [5] - Earnings are expected to increase by 43.8% YoY in 2026, reaching Rmb4.4 billion, with a product mix of 35% optical I&C, 35% marine systems, and 30% power transmission [5] - The company has revised its revenue forecasts for 2026 and 2027 upwards by 1.9% each, now expecting Rmb61.3 billion and Rmb67.7 billion respectively [32] Risks and Opportunities - Risks include slower-than-expected revenue growth in the optical I&C segment and subpar order intakes in overseas markets [31] - Opportunities arise from the growth of submarine cable demand due to offshore wind power capacity expansion [26] Consensus and Analyst Ratings - The consensus rating for ZTT is overwhelmingly "Overweight" with no "Equal-weight" or "Underweight" ratings [20] - Institutional ownership stands at 85.2%, indicating strong confidence from institutional investors [29] Additional Important Information - The company is expected to benefit from favorable structural tailwinds across its segments, particularly in optical fiber demand and power transmission growth [11][18] - The financial summary indicates a robust growth trajectory with significant increases in net profit and revenue across the forecasted years [9][33]

6 February 2026 | 8:59PM HKT Equity Research Qinghai Salt Lake Industry (000792.SZ) Accelerated growth outlook, potential first dividend in 10 years; upgrade to Buy 000792.SZ 12m Price Target: Rmb42.00 Price: Rmb32.40 Upside: 29.6% We revise up recurring earnings for QHL by 66% and 36% for 2026E and 2027E, to incorporate the recent asset injection of Yiliping lithium brine project, higher lithium price as a result of mark-to-market, and higher potash price assumptions. We also see improved clarity on QHL's ...

Summary of the Conference Call for Bio Co., Ltd. Industry and Company Overview - The conference call focused on Bio Co., Ltd., specifically its developments in the African Swine Fever (ASF) vaccine sector, which is a critical area in the animal health industry. Key Points and Arguments 1. **Positive Results from ASF Vaccine Trials** Bio Co., Ltd. reported successful results from its subunit ASF vaccine attack experiment, where no deaths occurred among the immunized group under an 8,000 HAD virus attack, indicating a high protection rate. This sets a solid foundation for subsequent clinical trials and approvals [2][3]. 2. **Upcoming Clinical Trials** The company plans to conduct a second attack experiment on April 12, aiming to verify the vaccine's effectiveness throughout its lifecycle. The completion of the second clinical trial is expected by late May or early June [2][3]. 3. **Market Approval Timeline** If the results are favorable, the China National Center for Animal Health (CNCA) may participate in the review process, potentially accelerating the approval timeline. The company anticipates obtaining a temporary production license by mid to late 2026, allowing for large-scale production [2][3]. 4. **Pricing Strategy** The initial pricing for the ASF vaccine is set at 25 RMB per dose, which balances affordability for farmers and the technological uniqueness of the product. The expected gross margin is projected to exceed 50%, indicating strong profitability potential [2][5]. 5. **Competitive Advantages** Bio Co., Ltd. is currently the only company certified by the Chinese Academy of Sciences to conduct clinical trials for the ASF vaccine, providing a significant competitive edge. The involvement of CNCA in the process is expected to expedite market entry [2][6][7]. 6. **Collaboration in Vietnam** The company is collaborating with local firms in Vietnam to promote the ASF vaccine, addressing the issue of local pig populations infected with recombinant viruses. They expect to obtain production licenses within six months and begin sales within 18 months [2][9]. 7. **Future Developments in mRNA Vaccines** Bio Co., Ltd. is also working on an mRNA vaccine for feline infectious peritonitis, projected to be launched domestically by 2028. The company is collaborating with two major U.S. pharmaceutical companies, utilizing a revenue-sharing model that could yield significant returns [3][10]. 8. **Overall Business Outlook for 2026** The company anticipates explosive growth in the ruminant service sector in 2026, driven by the ASF vaccine's market entry. The poultry business remains stable, and overall, the company expects positive trends across its various segments [3][12]. Additional Important Information - The company is currently focusing on testing the vaccine primarily for piglets, with plans for further discussions regarding its application for sows based on feedback from breeding farms [5]. - The competitive landscape includes other companies like Jinyu Biological, which has completed clinical trials but may face delays in large-scale production due to additional trial requirements [8]. - The fourth quarter's specific data on other products like swine foot-and-mouth disease vaccines is pending, but the ASF vaccine is expected to drive sales of existing products [11].

摘要 大丰实业 20260205 大丰实业受益于杭州亚运会，承接 80%场馆设施建设，吸引多国代表团 调研，海外市场需求旺盛，尤其在发达国家，文化体育场馆设施相对落 后。 公司海外订单显著增长，2024 年约为 3-4 亿元，预计 2025 年将达到 15-16 亿元，同比增长 4-5 倍，年底还有约 10 亿元订单待签署。国内 市场方面，2025 年新签订单预计 30 多亿元，主要选择高毛利、资金回 笼有保障的项目。 大丰实业计划 2026 年国内新签订单约 40 亿元，海外目标 20 亿元以上。 海外与国内订单确认周期相似，约为 12-18 个月，海外项目收款情况良 好，多数项目签约后能迅速收到 30%预付款。 公司积极发展 C 端文旅运营，截至 2025 年底运营 23 个场馆，全部实 现盈利，预计 2025 年营收可达 3-4 亿元，高于 2024 年的 1 亿多元。 通过优化内容引进，如脱口秀、舞台剧等，并积极与美国头部 IP 接洽。 大丰实业计划每年新增至少 5 个场馆，2026 年目标新增 10 个左右。通 过浙江大丰文化传媒公司进行 IP 对接，将芒果 TV 剧目改编为线下沉浸 式体验，如探案 ...

山西焦煤 20260205 摘要 2025 年前三季度商品煤综合售价为 780 元/吨，同比 2024 年同期的 1,070 元/吨大幅下降，导致业绩下滑。主焦煤价格在 2025 年 7 月触底 后逐步回升，至 10 月底恢复至 1,550 元/吨水平。 2026 年 2 月主焦煤价格下调 30 元/吨，反映了 1 月份市场钢厂降价呼 声及山西焦煤价格相对偏高。冬储情况与去年基本持平，发运量和竞拍 热情均表现正常。 焦炭提涨表明钢铁行业接受度尚可，但受春节因素影响，3 月份供需双 弱格局或将延续，预计价格保持平稳。原料端煤炭供给自去年开始明显 收缩，预计明年供给难有明显改善。 10 月至 11 月销量有所下降，具体数据待 12 月统计。年底成本进度不 均衡、减值测试（涉及五乡电厂、焦化厂等）及 2024 年薪酬兑现均对 业绩产生影响。8 月、9 月收入明显下降，员工工资降低约 25%。 新县区块煤矿全年利息约 5 亿元，按季度均匀分摊。五乡电厂商誉减值 后剩余约 2 亿元，预计 2026 年不会有大额减值，但需审计机构确认。 山西焦煤在 2025 年四季度的长协价均价是多少？相较于三季度有多少提升？ 2025 ...

Summary of Dongshan Precision's Conference Call Company Overview - **Company**: Dongshan Precision - **Industry**: PCB (Printed Circuit Board) and Optical Module Manufacturing Key Points Industry and Market Trends - Dongshan Precision is closely tied to major North American consumer electronics clients, benefiting from the innovation cycle expected between 2026 and 2028, including the iPhone 18 series and foldable models, which will significantly boost shipment volumes and performance [2][6] - Emerging technologies such as AI smartphones and AR glasses are anticipated to increase the demand for flexible printed circuits (FPC) [2][7] - The global optical chip shortage positions Dongshan Precision favorably after acquiring Sols, allowing it to operate in both optical module and optical chip sectors, potentially expanding market share and enhancing competitiveness [2][8] Financial Performance - Revenue has shown stable growth, increasing from 28 billion RMB in 2020 to 36.7 billion RMB in 2024, with a compound annual growth rate (CAGR) of approximately 7% [5] - For the first three quarters of 2025, revenue reached 27 billion RMB, reflecting a year-on-year growth of 2.3% despite overall weak consumer electronics demand [5] - Profitability has fluctuated, with a gross margin of 13.8% and a net margin of 4.5% in the first three quarters of 2025, but improvements are expected as loss-making assets are reduced [5][18] PCB Market Dynamics - The PCB market is projected to grow significantly, with the soft board market expected to rise from 12.8 billion USD in 2024 to 15.5 billion USD in 2029, a CAGR of about 4% [6] - High-end PCB demand is driven by AI applications and cloud infrastructure spending, which is expected to reach 271.5 billion USD by 2025, growing over 30% year-on-year [7][10] - The transition from 400G to 1.6T in switch technology is expected to multiply the value of PCBs used, with layer counts increasing from 24 to over 38 [11][10] Optical Module Market - The optical module market is forecasted to grow from 16.3 billion USD in 2024 to 39 billion USD by 2029, with a CAGR exceeding 20% [14] - High-speed optical modules, such as 800G, are expected to see significant growth, with a projected increase from 0.5 million USD in 2019 to 4.5 billion USD by 2024, a CAGR of 150% [14] - Dongshan Precision's vertical integration in the optical module business allows it to produce a range of products from 10G to 1.6T, with ongoing development of next-generation 3.2T products [17] Strategic Advantages - Dongshan Precision is the second-largest soft board manufacturer globally, with capabilities to produce boards as thin as 0.05 mm, widely used in AI smartphones and devices [15] - The company plans to invest up to 1 billion USD to expand high-end PCB production capacity to meet emerging market demands [15][16] - New technologies such as COP, intermediate backplane, and embedded technology are expected to enhance production efficiency and market space for PCBs [12][13] Future Outlook and Risks - Revenue projections for Dongshan Precision are 41.8 billion RMB in 2025, 46.7 billion RMB in 2026, and 80 billion RMB in 2027, with corresponding profits of 1.5 billion, 7.1 billion, and 9.95 billion RMB [18] - Despite a valuation below industry averages, risks include lower-than-expected downstream demand, insufficient new production capacity, and intensified industry competition [18] - Overall, the company is positioned as a strong player in the AI sector, making it a recommended investment opportunity [18]

Summary of the Conference Call for Dengkang Oral Care Company Overview - **Company**: Dengkang Oral Care - **Industry**: Oral Care Products Key Points Strategic Direction - The strategic tone for 2026 is "steady progress" with a focus on optimizing profitability through adjustments in e-commerce platform allocations [2][6][10] - Plans to reduce reliance on Douyin (TikTok) from over 40% to below 40%, maintain Tmall at around 30%, and increase JD's share to over 20% [2][5][7][10] E-commerce Performance - As of early 2026, overall profit margins across e-commerce platforms are stable at approximately 5-6%, with JD performing the best, followed by Tmall, and Douyin slightly below average [2][5][7] - The company aims to enhance profitability by reallocating resources to higher-margin platforms [5][16] Product Strategy - Dengkang is focusing on product premiumization, targeting an increase in ultra-high-end products (priced above 30 RMB) from 20% to around 30% of total sales [2][11][12] - The new keratin toothpaste launched in August 2025 has monthly sales exceeding 10 million RMB, with a target of 20-30 million RMB per month in 2026 [2][13] Market Trends and Challenges - The overall industry remains challenging, with many emerging brands operating at a loss, particularly on platforms like Douyin [9][21] - Despite a general decline in the oral care market, Dengkang has achieved nearly double-digit growth, contrasting with an industry decline of about 8% [21][22] Future Plans - 2026 is designated as the year for overseas market expansion, particularly in Southeast Asia, with a sales target of several million RMB [5][18] - The company plans to implement a three-step strategy for international expansion: brand establishment, building offline channels, and supply chain development [5][18] Manufacturing and Supply Chain - Dengkang employs a light asset operation model, outsourcing lower-end product manufacturing while maintaining high-end production in-house [19] - The inventory cycle is currently 30-40 days, significantly shorter than the industry average of 90-120 days, indicating efficient inventory management [16] Investment and Growth Areas - Future investments will focus on the oral health ecosystem, including smart oral care and digital transformation [24][25] - The company is also exploring mergers and acquisitions to enhance growth potential in the oral care sector [24] Shareholder Actions - Shareholder reduction plans are based on individual decisions, with expectations for future stock price growth influencing timing [26] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Dengkang Oral Care's focus on profitability, product premiumization, and market expansion.